Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2014 (2014), Article ID 541810, 5 pages
Clinical Study

Propranolol in Treatment of Huge and Complicated Infantile Hemangiomas in Egyptian Children

1Pediatrics Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
2Surgery Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt

Received 25 February 2014; Revised 21 April 2014; Accepted 24 April 2014; Published 8 May 2014

Academic Editor: Giuseppe Argenziano

Copyright © 2014 Basheir A. Hassan and Khalid S. Shreef. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Infantile hemangiomas (IHs) are the most common benign tumours of infancy. Propranolol has recently been reported to be a highly effective treatment for IHs. This study aimed to evaluate the efficacy and side effects of propranolol for treatment of complicated cases of IHs. Patients and Methods. This prospective clinical study included 30 children with huge or complicated IHs; their ages ranged from 2 months to 1 year. They were treated by oral propranolol. Treatment outcomes were clinically evaluated. Results. Superficial cutaneous hemangiomas began to respond to propranolol therapy within one to two weeks after the onset of treatment. The mean treatment period that was needed for the occurrence of complete resolution was 9.4 months. Treatment with propranolol was well tolerated and had few side effects. No rebound growth of the tumors was noted when propranolol dosing stopped except in one case. Conclusion. Propranolol is a promising treatment for IHs without obvious side effects. However, further studies with longer follow-up periods are needed.